TapewireFind a company

person · Reporting owner

MILNE GEORGE M JR

Disclosed activity across 3 companies

Tapewire entity
40611
SEC CIK
0001179552

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Amylyx Pharmaceuticals, Inc.AMLX · Entity 259DirectorOctober 05, 2026October 07, 2026
Aurinia Pharmaceuticals Inc.AUPH · Entity 4463DirectorMay 18, 2023May 23, 2023
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398DirectorMay 07, 2021May 10, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Amylyx Pharmaceuticals, Inc.

Report date October 05, 2026 · Filed October 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect782,881 Reported balance After 2026-10-05 transaction · row 1
1 source row

Row 1 · 2026-10-05 · Sale · Disposed 30,000 · Balance 782,881

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 28, 2026.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 28, 2026.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Aurinia Pharmaceuticals Inc.

Report date May 18, 2023 · Filed May 23, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect78,733 Reported balance After 2023-05-18 transaction · row 1
1 source row

Row 1 · 2023-05-18 · Exercise / conversion · Acquired 8,733 · Balance 78,733

F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2023-05-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2023-05-18 · Exercise / conversion · Disposed 8,733 · Balance 0

F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Report date May 07, 2021 · Filed May 10, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect29,079 Ending reported balance After 2021-05-07 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2021-05-07 · Grant · Acquired 355 · Balance 28,772

F1: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.

Row 2 · 2021-05-07 · Grant · Acquired 307 · Balance 29,079

F2: The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting of shareholders.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $342.55 · Expires 2031-05-07Direct1,151 Reported balance After 2021-05-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2021-05-07 · Grant · Acquired 1,151 · Balance 1,151

F3: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.

Common StockSEC Table I · non-derivativeIndirectHeld By Spouse1,000 Reported balance Holding disclosure · report date 2021-05-07 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 1,000

Filing footnotes · ownership attribution and instrument terms

F1: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.

F2: The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting of shareholders.

F3: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 05, 2026 Filed Oct 7, 2026 20:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 30,000 $27.70 $830,904.00
Disclosure

SEC source: 0001193125-26-416950 · ownership.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 782,881

F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 28, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 24,372 $0.00 Strike: $14.31 $0.00
Disclosure

SEC source: 0001193125-26-261638 · ownership.xml · derivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,372

Underlying: Common Stock · 24,372 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:08 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GiftCommon Stock 17,780 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-012921 · ownership.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 812,881

F1 · kind: Represents a bona fide gift for no consideration.

Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:06 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $5.05 $0.00
Disclosure

SEC source: 0000950170-25-083713 · ownership.xml · derivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
January 24, 2025 Filed Jan 28, 2025 21:55 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GiftCommon Stock 27,910 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-009913 · ownership.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 830,661

F1 · kind: Represents a bona fide gift for no consideration.

F2 · shares: These shares of common stock remain subject to a lock-up agreement pursuant to which they cannot be sold prior to March 11, 2025 without the consent of Leerink Partners LLC, subject to certain exceptions.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 23:26 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 PurchaseCommon Stock 100,000 $2.20 $219,800.00
Disclosure

SEC source: 0000950170-24-104186 · ownership.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 858,571

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.14 to $2.235. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 06, 2024 Filed Jun 7, 2024 20:44 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $1.76 $0.00
Disclosure

SEC source: 0000950170-24-070778 · ownership.xml · derivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 6, 2025 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
January 25, 2024 Filed Jan 29, 2024 21:38 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GiftCommon Stock 9,100 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-008347 · ownership.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 758,571

Read SEC document
January 16, 2024 Filed Jan 18, 2024 21:50 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GiftCommon Stock 94,350 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-005437 · ownership.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 767,671

Read SEC document
June 08, 2023 Filed Jun 12, 2023 23:46 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 16,985 $0.00 Strike: $26.25 $0.00
Disclosure

SEC source: 0000899243-23-015410 · doc4.xml · derivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,985

Underlying: Common Stock · 16,985 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
May 18, 2023 Filed May 23, 2023 21:16 UTC Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 Exercise / conversionRestricted Stock Units · Derivative 8,733 $0.00 $0.00
Disclosure

SEC source: 0001600620-23-000019 · wk-form4_1684876599.xml · derivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,733 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date.

F1 · derivative.expiration_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date.

Read SEC document
May 18, 2023 Filed May 23, 2023 21:16 UTC Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 Exercise / conversionCommon Stock 8,733 Not disclosed Not disclosed
Disclosure

SEC source: 0001600620-23-000019 · wk-form4_1684876599.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,733

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date.

Read SEC document
March 16, 2023 Filed Mar 21, 2023 00:25 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 1,916 $32.45 $62,171.71
Disclosure

SEC source: 0000899243-23-009179 · doc4.xml · nonDerivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 862,021

F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 16, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.30 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 16, 2023 Filed Mar 21, 2023 00:25 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 33,084 $31.86 $1,053,900.75
Disclosure

SEC source: 0000899243-23-009179 · doc4.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 863,937

F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 16, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.30 to $32.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 02, 2023 Filed Mar 6, 2023 21:29 UTC Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 PurchaseCommon Stock 20,000 $8.91 $178,284.00
Disclosure

SEC source: 0001628280-23-006533 · wf-form4_167813818041525.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $8.86 to $8.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
December 29, 2022 Filed Feb 14, 2023 21:35 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GiftCommon Stock 13,800 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-004990 · doc5.xml · nonDerivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 897,021

Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:05 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (Right to Buy) · Derivative 19,000 $0.00 Strike: $13.56 $0.00
Disclosure

SEC source: 0000899243-22-021889 · doc4.xml · derivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.

Read SEC document
May 18, 2022 Filed May 20, 2022 20:10 UTC Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 GrantStock Option (right to buy) · Derivative 14,612 $0.00 Strike: $11.45 $0.00
Disclosure

SEC source: 0001628280-22-015035 · wf-form4_165307739688602.xml · derivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,612

Underlying: Common Stock · 14,612 shares

Expires 2032-05-18

F2 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on June 18, 2022.

Read SEC document
May 18, 2022 Filed May 20, 2022 20:10 UTC Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 GrantRestricted Stock Unit · Derivative 8,733 $0.00 $0.00
Disclosure

SEC source: 0001628280-22-015035 · wf-form4_165307739688602.xml · derivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,733

Underlying: Common Shares · 8,733 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant.

F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant.

F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:06 UTC Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 PurchaseCommon Stock 5,000 $10.82 $54,100.00
Disclosure

SEC source: 0001628280-22-005381 · wf-form4_164677357726147.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $10.81 to $10.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
January 06, 2022 Filed Jan 11, 2022 01:34 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (Right to Buy) · Derivative 8,400 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-22-001521 · doc4.xml · derivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,400

Underlying: Common Stock · 8,400 shares

Expires 2032-01-06

F1 · derivative.exercise_date: This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
January 06, 2022 Filed Jan 11, 2022 01:34 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 PurchaseCommon Stock 26,315 $19.00 $499,985.00
Disclosure

SEC source: 0000899243-22-001521 · doc4.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,396

Read SEC document
January 06, 2022 Filed Feb 14, 2023 21:35 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 ConversionSeries C-2 Preferred Stock · Derivative 23,212 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-004990 · doc5.xml · derivative · entry 6

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,212 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

Read SEC document
January 06, 2022 Filed Feb 14, 2023 21:35 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 ConversionSeries C-1 Preferred Stock · Derivative 19,482 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-004990 · doc5.xml · derivative · entry 5

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,482 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

Read SEC document
January 06, 2022 Filed Feb 14, 2023 21:35 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 ConversionSeries B Preferred Stock · Derivative 384,449 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-004990 · doc5.xml · derivative · entry 4

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 384,449 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

Read SEC document
January 06, 2022 Filed Feb 14, 2023 21:35 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 ConversionSeries A Preferred Stock · Derivative 262,282 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-004990 · doc5.xml · derivative · entry 3

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 262,282 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

Read SEC document
January 06, 2022 Filed Feb 14, 2023 21:35 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 ConversionCommon Stock 689,425 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-23-004990 · doc5.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 910,821

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

Read SEC document
June 14, 2021 Filed Jun 17, 2021 01:20 UTC Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 GrantStock Option (right to buy) · Derivative 31,347 $0.00 Strike: $12.86 $0.00
Disclosure

SEC source: 0001628280-21-012386 · wf-form4_162389281306609.xml · derivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,347

Underlying: Stock Option (right to buy) · 31,347 shares

Expires 2031-06-14

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on July 14, 2021.

Read SEC document
May 07, 2021 Filed May 10, 2021 21:39 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GrantStock Options (Right to Buy) · Derivative 1,151 $0.00 Strike: $342.55 $0.00
Disclosure

SEC source: 0001127602-21-016113 · form4.xml · derivative · entry 4

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,151

Underlying: Common Stock · 1,151 shares

Expires 2031-05-07

F3 · shares: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.

Read SEC document
May 07, 2021 Filed May 10, 2021 21:39 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GrantCommon Stock 307 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-016113 · form4.xml · nonDerivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,079

F2 · shares: The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting of shareholders.

Read SEC document
May 07, 2021 Filed May 10, 2021 21:39 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GrantCommon Stock 355 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-016113 · form4.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,772

F1 · shares: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.

Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:25 UTC Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 PurchaseCommon Stock 5,000 $13.00 $65,000.00
Disclosure

SEC source: 0001628280-21-004265 · wf-form4_161532509442005.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.995 to $13.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:47 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 Exercise / conversionStock Options (Right to Buy) · Derivative 3,530 $0.00 Strike: $52.29 $0.00
Disclosure

SEC source: 0001127602-21-008742 · form4.xml · derivative · entry 4

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,530 shares

Expires 2021-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:47 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 SaleCommon Stock 3,530 $290.01 $1,023,730.01
Disclosure

SEC source: 0001127602-21-008742 · form4.xml · nonDerivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,417

F1 · price: This transaction was executed in multiple trades at prices ranging from $290.00 to $290.175. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:47 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 Exercise / conversionCommon Stock 3,530 $52.29 $184,583.70
Disclosure

SEC source: 0001127602-21-008742 · form4.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,947

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 11, 2020 Filed May 12, 2020 18:23 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GrantStock Options (Right to Buy) · Derivative 2,539 $0.00 Strike: $164.24 $0.00
Disclosure

SEC source: 0001127602-20-016255 · form4.xml · derivative · entry 4

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,539

Underlying: Common Stock · 2,539 shares

Expires 2030-05-11

F3 · derivative.exercise_date: The Stock Options become exercisable upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders.

Read SEC document
May 11, 2020 Filed May 12, 2020 18:23 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GrantCommon Stock 639 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-016255 · form4.xml · nonDerivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,417

F2 · shares: The grant was made in lieu of director service fees for the term commencing May 6, 2020. The restricted stock units vest upon the earlier of 5/11/2021, or the business day prior to the Company's next annual meeting of shareholders.

Read SEC document
May 11, 2020 Filed May 12, 2020 18:23 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GrantCommon Stock 741 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-016255 · form4.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,778

F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders.

Read SEC document
February 18, 2020 Filed Feb 19, 2020 15:41 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 Exercise / conversionStock Options (Right to Buy) · Derivative 3,140 $0.00 Strike: $70.29 $0.00
Disclosure

SEC source: 0001127602-20-006257 · form4.xml · derivative · entry 6

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,140 shares

Expires 2020-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2020 Filed Feb 19, 2020 15:41 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 Exercise / conversionStock Options (Right to Buy) · Derivative 4,030 $0.00 Strike: $43.39 $0.00
Disclosure

SEC source: 0001127602-20-006257 · form4.xml · derivative · entry 5

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,030 shares

Expires 2020-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2020 Filed Feb 19, 2020 15:41 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 SaleCommon Stock 7,170 $176.07 $1,262,429.79
Disclosure

SEC source: 0001127602-20-006257 · form4.xml · nonDerivative · entry 3

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,037

F1 · price: This transaction was executed in multiple trades at prices ranging from $175.70 to $176.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 18, 2020 Filed Feb 19, 2020 15:41 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 Exercise / conversionCommon Stock 3,140 $70.29 $220,710.60
Disclosure

SEC source: 0001127602-20-006257 · form4.xml · nonDerivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,207

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2020 Filed Feb 19, 2020 15:41 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 Exercise / conversionCommon Stock 4,030 $43.39 $174,861.70
Disclosure

SEC source: 0001127602-20-006257 · form4.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,067

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 22, 2019 Filed May 23, 2019 17:30 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GrantCommon Stock 812 $0.00 $0.00
Disclosure

SEC source: 0001127602-19-019572 · form4.xml · nonDerivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,037

F2 · kind: This grant was made in lieu of director service fees for the term commencing May 21, 2019. The restricted stock units vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders.

Read SEC document
May 22, 2019 Filed May 23, 2019 17:30 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GrantCommon Stock 1,882 $0.00 $0.00
Disclosure

SEC source: 0001127602-19-019572 · form4.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,225

F1 · kind: Consists of 1,882 unvested restricted stock units that vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders.

Read SEC document
February 22, 2019 Filed Feb 25, 2019 15:12 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 Exercise / conversionStock Options (Right to Buy) · Derivative 4,540 $0.00 Strike: $33.93 $0.00
Disclosure

SEC source: 0001127602-19-007889 · form4.xml · derivative · entry 4

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,540 shares

Expires 2019-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 22, 2019 Filed Feb 25, 2019 15:12 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 SaleCommon Stock 4,540 $143.00 $649,220.00
Disclosure

SEC source: 0001127602-19-007889 · form4.xml · nonDerivative · entry 2

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,343

Read SEC document
February 22, 2019 Filed Feb 25, 2019 15:12 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 Exercise / conversionCommon Stock 4,540 $33.93 $154,042.20
Disclosure

SEC source: 0001127602-19-007889 · form4.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,883

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 03, 2018 Filed Feb 1, 2019 18:08 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GiftCommon Stock 5,240 $0.00 $0.00
Disclosure

SEC source: 0001127602-19-003337 · form5.xml · nonDerivative · entry 1

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,343

Read SEC document
May 14, 2018 Filed May 15, 2018 20:14 UTC CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 GrantCommon Stock 839 $0.00 $0.00
Disclosure

SEC source: 0001127602-18-017521 · form4.xml · nonDerivative · entry 3

MILNE GEORGE M JR · CIK 0001179552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,583

F2 · kind: This grant was made in lieu of director service fees for the term commencing May 8, 2018. The restricted stock units vest upon the earlier of 5/14/2019 or the business day prior to the Company's next annual meeting of shareholders.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.